Status message

Not the entire site translated, but only to "Journal"

SECOND GENERATION ANTIPSYCHOTICS IN ACUTE AND LONG-TERM TREATMENT OF SCHIZOPHRENIA: A CRITICAL REVIEW OF SCIENTIFIC DATA

G.M. Usov
Omsk State Medical University of Ministry of Health of Russian Federation, 
Omsk, Russia

Summary. Second generation antipsychotics (SGA) expended our abilities in treatment of schizophrenia and reduced risk of extrapyramidal side effects. But early understanding of SGAs’ total superiority above first generation antipsychotics (FGA) were not confirmed. Nowadays we have strong evidences of some differences between antipsychotics, but most of them are gradual rather than discrete. Differences in side-effects are more marked.
Paliperidone palmitate is long-acting intramuscular SGA. It was found more effective than oral FGA and SGA in reduction of productive and negative symptoms of schizophrenia, quality of remission and social functioning. One-month paliperidone palmitate (xeplion) could be prescribed in acute-phase therapy. Three-month paliperidone palmitate (trevicta) discovered new unique options for long-term treatment.

Contact: Usov Grigory, usovgm@list.ru, https//orcid.org/0000-0002-7619-1179
Citation: Usov G.M. Second Generation Antipsychotics in Acute and Long-Term Treatment of  Schizophrenia: a Critical Review of Scientific Data // Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders]. – 2020. – No. 4. – P. 28–35. – DOI: 10.21265/PSYPH.2020.94.92.004 [in Russian] 
Conflict of interest: non declared.
 

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1.    Zharkova N.B. Perekhod k terapii atipichnymi antipsikhoticheskimi sredstvami – vopros strategii ili taktiki psikhofarmakoterapii? // Psikhiatriya i psikhofarmakoterapiya. – 2001. – № 1. – S. 12–16.
2.    Kalinin V.V., Ryvkin P.V. Atipichnye neiroleptiki v psikhiatrii: pravda i vymysel // Psikhiatriya i psikhofarmakoterapiya. – 1999. – № 1. – S. 15–19.
3.    Kalinin V.V. K probleme otgranicheniya novykh neiroleptikov ot klassicheskikh. Sopostavlenie klinicheskogo i neirokhimicheskogo podkhodov // Psikhiatriya i psikhofarmakoterapiya. – 2001. – № 4. – S. 129–132.
4.    Mosolov S.N., Kalinin V.V., Eremin A.V. Cravnitel'naya effektivnost' i perenosimost' novogo pokoleniya antipsikhoticheskikh sredstv pri lechenii obostrenii shizofrenii (meta-analiz original'nykh issledovanii olanzapina, risperidona, kvetiapina, klozapina i galoperidola) // Novye dostizheniya v terapii psikhicheskikh zabolevanii. – M.: BINOM, 2002. – S. 82–94.
5.    Chetvertnykh I.I., Mosolov S.N., Kalinin V.V. i dr. Sravnitel'naya effektivnost' i perenosimost' dlitel'nogo primeneniya risperidona, kvetiapina i olanzapina v sravnenii s galoperidolom u bol'nykh s vpervye vyyavlennoi shizofreniei (otkrytoe randomizirovannoe issledovanie) // Psikhiatriya i psikhofarmakoterapiya. – 2005. – № 4. – S. 189–192.
6.    Borodin V.I., Akhapkin R.V. Preimushchestva zameny traditsionnykh neiroleptikov na olanzapin pri terapii bol'nykh shizofreniei // Psikhiatriya i psikhofarmakoterapiya. – 2005. – № 4. – S. 270–273.
7.    Mazaeva N.A. Riski i preimushchestva primeneniya atipichnykh antipsikhotikov v psikhiatrii (po dannym zarubezhnykh publikatsii poslednikh let) // Psikhiatriya i psikhofarmakoterapiya. – 2006. – № 5. – S. 3–11.
8.    Snedkov E.V. Atipichnye antipsikhotiki: poisk resheniya starykh i novykh problem // Psikhiatriya i psikhofarmakoterapiya. – 2006. – № 4. – S. 45–50.
9.    Lieberman J.A., Stroup T.S., McEvoy J.P. et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia // N Engl J Med. – 2005. – Vol. 353. – P. 1209–1223. – DOI: 10.1056/NEJMoa051688
10.    Jauhar S., Guloksuz S., Andlauer O. et al. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? // BMC Psychiatry. – 2012. Vol. 12. – P. 27. – DOI: 10.1186/1471-244X-12-27
11.    Mosolov S.N. Spornye i maloizuchennye voprosy prakticheskogo ispol'zovaniya antipsikhoticheskoi farmakoterapii u bol'nykh shizofreniei (analiz rezul'tatov interaktivnogo oprosa vrachei) // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2006. – Vol. 1. – P. 41–48.
12.    Manschreck T.C., Boshes R.A. The CATIE Schizophrenia Trial: Results, Impact, Controversy // Harvard Review of Psychiatry. –2007, Sept.–Oct. – Vol. 15, No. 5. – P. 245–58. – DOI: 10.1080/10673220701679838
13.    Miller D.D., Caroff S.N., Davis S.M. et al. Extrapyramidal side-effects of antipsychotics in a randomised trial // Br J Psychiatry. – 2008, Oct. – Vol. 193 (4). – P. 279–88.
14.    Leucht S., Corves C., Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis // Lancet. – 2009, Jan 3. – Vol. 373 (9657). – P. 31–41. – DOI: 10.1016/S0140-6736(08)61764-X
15.    Ray W.A., Chung C.P., Murray K.T. et al. Atypical antipsychotic drugs and the risk of sudden cardiac death // N Engl J Med. – 2009, Jan 15. – Vol. 360 (3). – P. 225–235.
16.    Kahn R.S., Fleischhacker W.W., Boter H. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial // Lancet. – 2008, Mar 29. – Vol. 371 (9618). – P. 1085–1097.
17.    Leucht S., Cipriani A., Spineli L. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis // Lancet. – 2013. – Vol. 382. – P. 951–962. – DOI: 10.1016/S0140-6736(13)60733-3
18.    Huhn M., Nikolakopoulou A., Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis // Lancet. – 2019. –Vol. 394. – P. 939–951.
19.    World Health Organization Model List of Essential Medicines. 21st List, 2019. – Geneva: World Health Organization, 2019. – Available at: https://www.who.int/medicines/publications/essentialmedicines/en/ (accessed May, 12, 2020).
20.    Schatzberg A.F., DeBattista C. Manual of clinical psychopharmacology. – 9th ed. – Washington DC: American Psychiatric Publishing, Inc., 2019. 
21.    Mosolov S.N., Tsukarzi E.E., Kapiletti S.G. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam. // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. M.: Sotsial'no-politicheskaya mysl', 2012. S. 11–61.
22.    Mosolov S.N., Tsukarzi E.E. Psikhofarmakoterapiya shizofrenii // Psikhiatriya: natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: GEOTAR-Media, 2018. – S. 299–328.
23.    Shizofreniya: klinicheskie rekomendatsii.. Proekt [Elektronnoe izdanie] / Rossiiskoe obshchestvo psikhiatrov. M., 2019. 119 s. https://psychiatr.ru/download/4244?view=1&name=KR_+Shizofreniya+25-11.pdf
24.    Hasan A., Falkai P., Wobrock T. et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance // The World Journal of Biological Psychiatry. – 2012. – Vol. 13. – P. 318–378.
25.    Medvedev V.E. Vozmozhnost' i obosnovannost' perevoda na atipichnye antipsikhotiki bol'nykh shizofreniei // Psikhiatriya i psikhofarmakoterapiya. – 2013. – № 5. – S. 23–28.
26.    Usov G.M., Sheveleva K.P. Evolyutsiya podkhodov k kupiruyushchei terapii antipsikhotikami pervogo v zhizni psikhoza pri shizofrenii i rasstroistvakh shizofrenicheskogo spektra (20-letnee retrospektivnoe issledovanie) // Sotsial'naya i klinicheskaya psikhiatriya. – 2020. – T. 30, № 3. – S. 55–61.
27.    McEvoy J.P., Byerly M., Hamer R.M. et al. Effectiveness of Paliperidone Palmitate vs. Haloperidol Decanoate for Maintenance Treatment of Schizophrenia: A Randomized Clinical Trial // JAMA. – 2014, May 21. – Vol. 311 (19). – P. 1978–1987. DOI: 10.1001/jama.2014.4310
28.    Nielsen J., Jensen S.O.W., Friis R.B. et al. Comparative Effectiveness of Risperidone Long-Acting Injectable vs First-Generation Antipsychotic Long-Acting Injectables in Schizophrenia: Results From a Nationwide, Retrospective Inception Cohort Study // Schizophr Bull. – 2015, May. – Vol. 41 (3). – P. 627–636. DOI: 10.1093/schbul/sbu128
29.    Stone J.M., Roux S., Taylor D. et al. First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse // Ther Adv Psychopharmacol. – 2018, Dec. – Vol. 8 (12). – P. 333–336. – DOI: 10.1177/2045125318795130
30.    Gorobets L.N., Litvinov A.V., Polyakovskaya T.P. Psikhoendokrinologicheskie aspekty perenosimosti prolongirovannykh form antipsikhotikov u bol'nykh s rasstroistvami shizofrenicheskogo spektra // Psikhiatriya i psikhofarmakoterapiya. – 2013. – № 4. – S. 22–29.
31.    Petrova N.N., Ivanov M.V., Kosterin D.N. i dr. Kharakteristika remissii u bol'nykh shizofreniei na fone lecheniya antipsikhoticheskimi preparatami prolongirovannogo deistviya // Psikhiatriya i psikhofarmakoterapiya. – 2015. – № 5–6. – S. 20–25.
32.    Avrutskii G.Ya., Neduva A.A. Lechenie psikhicheski bol'nykh. – 2-e izd. – M.: Meditsina, 1988. – 528 s.
33.    Mosolov S.N. Osnovy psikhofarmakoterapii. – M.: Vostok/Zapad, 1996. – 288 s.
34.    Bykov Yu.V., Bekker R.A. Prolongirovannye i sverkhprolongirovannye antipsikhotiki v podderzhivayushchei terapii shizofrenii: kogda, kak, komu? // Psikhiatriya i psikhofarmakoterapiya. – 2019. – Vol. 21 (5). – P. 10–15.
35.    Keith S. Advances in psychotropic formulations // Prog Neuropsychopharmacol Biol Psychiatry. – 2006, Aug 30. – Vol. 30 (6). – P. 996–1008. – DOI: 10.1016/j.pnpbp.2006.03.031
36.    Vermeir M., Naessens I., Remmerie B. et al. Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist // Humans Drug Metabolism and Disposition. – 2008. – Vol. 36. – P. 769–779.
37.    Schreiner A., Svensson A., Wapenaar R. et al. Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS) // World J Biol Psychiatry. – 2014, Sep. – Vol. 15 (7). – P. 534–545.
38.    Schreiner A., Aadamsoo, Altamura A.C. et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia // Schizophr Res. – 2015. – DOI: 10.1016/j.schres.2015.08.015
39.    Schreiner A., Bergmans P., Cherubin P. A prospective flexible-dose study of Paliperidone palmitatein nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents // Clinical Therapeutics. – 2014. – Vol. 36, No. 10. – DOI: 10.1016/j.clinthera.2014.08.014
40.    Hargarter L., Cherubin P., Bergmans P. et al. Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics // Progress in Neuro-Psychopharmacology & Biological Psychiatry. – 2015. – Vol. 58. – P. 1–7.
41.    Pandina G.J., Lindenmayer J.-P., Lull J. et al. A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia // Journal of Clinical Psychopharmacology. – 2010. – Vol. 30, No. 3. – P. 235–244.
42.    Hargarter L., Bergmans P., Cherubin P. et al. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia // Expert Opinion on Pharmacotherapy. – 2016. Vol. 17 (8). – P. 1043–1053. – DOI: 10.1080/14656566.2016.1174692
43.    Attard A., Olofinjana O., Cornelius V. et al. Paliperidone palmitate long-acting injection – prospective year-long follow-up of use in clinical practice // Acta Psychiatr Scand. – 2014. – Vol. 130. – P. 46–51. – DOI: 10.1111/acps.12201
44.    Savitz A.J., Xu H., Gopal S. et al. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study // International Journal of Neuropsychopharmacology. – 2016. – Vol. 19, Suppl. 1. – P. 6. – DOI: 10.1093/ijnp/pyw018
45.    Garcia-Portilla M.P., Llorca P.-M., Maina G. et al. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia // Ther Adv Psychopharmacol. – 2020. – Vol. 10. – P. 1–20. – DOI: 10.1177/2045125320926347
46.    Berwaerts J., Liu Y., Gopal S. et al. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia. A Randomized Clinical Trial // JAMA Psychiatry. – 2015. – Vol. 72 (8). – P. 830–839. – DOI: 10.1001/jamapsychiatry.2015.0241